peptide backbone comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
In the colonies of a few ant species, there are physical castes—workers in distinct size-classes, called minor (micrergates), median, and major ergates (macrergates). Often, the larger ants have disproportionately larger heads, and correspondingly stronger mandibles. Although formally known as dinergates, such individuals are sometimes called "soldier" ants because their stronger mandibles make them more effective in fighting, although they still are workers and their "duties" typically do not vary greatly from the minor or median workers. In a few species, the median workers are absent, creating a sharp divide between the minors and majors. Weaver ants, for example, have a distinct bimodal size distribution. Some other species show continuous variation in the size of workers. The smallest and largest workers in Carebara diversa show nearly a 500-fold difference in their dry weights. Workers cannot mate; however, because of the haplodiploid sex-determination system in ants, workers of a number of species can lay unfertilised eggs that become fully fertile, haploid males. The role of workers may change with their age and in some species, such as honeypot ants, young workers are fed until their gasters are distended, and act as living food storage vessels. These food storage workers are called repletes. For instance, these replete workers develop in the North American honeypot ant Myrmecocystus mexicanus.
In the 1969 election, the SPD gained enough votes to form a coalition government with the FDP. SPD leader and Chancellor Willy Brandt remained head of government until May 1974, when he resigned after the Guillaume affair, in which a senior member of his staff was uncovered as a spy for the East German intelligence service, the Stasi. However, the affair is widely considered to have been merely a trigger for Brandt's resignation, not a fundamental cause. Instead, Brandt, dogged by scandal relating to alcohol and depression as well as the economic fallout of the 1973 oil crisis, almost seems simply to have had enough. As Brandt himself later said, "I was exhausted, for reasons which had nothing to do with the process going on at the time". Finance Minister Helmut Schmidt (SPD) then formed a government, continuing the SPD–FDP coalition. He served as Chancellor from 1974 to 1982. Hans-Dietrich Genscher, a leading FDP official, was Vice-Chancellor and Foreign Minister in the same years. Schmidt, a strong supporter of the European Community (EC) and the Atlantic alliance, emphasised his commitment to "the political unification of Europe in partnership with the USA". The goals of SPD and FDP drifted apart in the late 1970s and early 1980s. On 1 October 1982 the FDP joined forces with the CDU/CSU to elect CDU Chairman Helmut Kohl as Chancellor in a constructive vote of no confidence. Following national elections in March 1983, Kohl emerged in firm control of both the government and the CDU.
==== MeSH D12.776.556.579.374 – nonheme iron proteins ==== MeSH D12.776.556.579.374.187 – hemerythrin MeSH D12.776.556.579.374.281 – inositol oxygenase MeSH D12.776.556.579.374.375 – iron-sulfur proteins MeSH D12.776.556.579.374.375.025 – adrenodoxin MeSH D12.776.556.579.374.375.150 – ferredoxin-nitrite reductase MeSH D12.776.556.579.374.375.275 – ferredoxins MeSH D12.776.556.579.374.375.275.450 – molybdoferredoxin MeSH D12.776.556.579.374.375.275.725 – rubredoxins MeSH D12.776.556.579.374.375.637 – iron regulatory protein 1 MeSH D12.776.556.579.374.375.818 – iron regulatory protein 2 MeSH D12.776.556.579.374.375.863 – electron transport complex i MeSH D12.776.556.579.374.375.863.500 – nadh dehydrogenase MeSH D12.776.556.579.374.375.909 – electron transport complex ii MeSH D12.776.556.579.374.375.909.500 – succinate dehydrogenase MeSH D12.776.556.579.374.375.954 – electron transport complex iii MeSH D12.776.556.579.374.375.977 – nitrate reductase (nad(p)h) MeSH D12.776.556.579.374.375.988 – nitrate reductase (nadph) MeSH D12.776.556.579.374.450 – lipoxygenase MeSH D12.776.556.579.374.450.025 – arachidonate lipoxygenases MeSH D12.776.556.579.374.450.025.020 – arachidonate 5-lipoxygenase MeSH D12.776.556.579.374.450.025.025 – arachidonate 12-lipoxygenase MeSH D12.776.556.579.374.450.025.030 – arachidonate 15-lipoxygenase MeSH D12.776.556.579.374.687 – retinal dehydrogenase MeSH D12.776.556.579.374.925 – tyrosine 3-monooxygenase
Flutamide has been found to be effective in the treatment of hirsutism (excessive body/facial hair growth) in numerous studies. It possesses moderate effectiveness for this indication, and the overall quality of the evidence is considered to be moderate. The medication shows equivalent or superior effectiveness to other antiandrogens including spironolactone, cyproterone acetate, and finasteride in the treatment of hirsutism, although its relatively high risk of hepatotoxicity makes it unfavorable compared to these other options. It has been used to treat hirsutism at dosages ranging from 62.5 mg/day to 750 mg/day. A study found that multiple dosages of flutamide significantly reduced hirsutism in women with polycystic ovary syndrome and that there were no significant differences in the effectiveness for dosages of 125 mg/day, 250 mg/day, and 375 mg/day. In addition, a study found that combination of 125 mg/day flutamide with finasteride was no more effective than 125 mg/day flutamide alone in the treatment of hirsutism. These findings support the use of flutamide at lower doses for hirsutism without loss of effectiveness, which may help to lower the risk of hepatotoxicity. However, the risk has been found to remain even at very low doses.
Sources: en.wikipedia.org
reacts with acids, releasing carbonic acid which quickly disintegrates into carbon dioxide and water: CaCO3(s) + 2 H+(aq) → Ca2+(aq) + CO2(g) + H2O(l) releases carbon dioxide upon heating, called a thermal decomposition reaction, or calcination (to above 840 °C in the case of CaCO3), to form calcium oxide, CaO, commonly called quicklime, with reaction enthalpy 178 kJ/mol: CaCO3(s) → CaO(s) + CO2(g) reacts with gaseous hydrogen to form methane and water vapor plus solid calcium oxide or calcium hydroxide depending on temperature and product gas composition. Various metals including palladium and nickel are catalysts for the reaction. Calcium carbonate reacts with water that is saturated with carbon dioxide to form the soluble calcium bicarbonate.
=== Acute calculous cholecystitis === Gallstones blocking the flow of bile account for 90% of cases of cholecystitis (acute calculous cholecystitis). Blockage of bile flow leads to thickening and buildup of bile causing an enlarged, red, and tense gallbladder. The gallbladder is initially sterile but often becomes infected by bacteria, predominantly E. coli, Klebsiella, Streptococcus, and Clostridium species. Inflammation can spread to the outer covering of the gallbladder and surrounding structures such as the diaphragm, causing referred right shoulder pain.
Methane pyrolysis is an industrial process for "turquoise" hydrogen production from methane by removing solid carbon from natural gas. This one-step process produces hydrogen in high volume at low cost (less than steam reforming with carbon sequestration). No greenhouse gas is released. No deep well injection of carbon dioxide is needed. Only water is released when hydrogen is used as the fuel for fuel-cell electric heavy truck transportation, gas turbine electric power generation, and hydrogen for industrial processes including producing ammonia fertilizer and cement. Methane pyrolysis is the process operating around 1065 °C for producing hydrogen from natural gas that allows removal of carbon easily (solid carbon is a byproduct of the process). The industrial quality solid carbon can then be sold or landfilled and is not released into the atmosphere, avoiding emission of greenhouse gas (GHG) or ground water pollution from a landfill. In 2015, a company called Monolith Materials built a pilot plant in Redwood City, CA to study scaling Methane Pyrolysis using renewable power in the process. A successful pilot project then led to a larger commercial-scale demonstration plant in Hallam, Nebraska in 2016. As of 2020, this plant is operational and can produce around 14 metric tons of hydrogen per day. In 2021, the US Department of Energy backed Monolith Materials' plans for major expansion with a $1B loan guarantee. The funding will help produce a plant capable of generating 164 metric tons of hydrogen per day by 2024.
=== Pharmacodynamics === 4-Fluoroselegiline is a selective and irreversible inhibitor of monoamine oxidase B and monoaminergic activity enhancer. A radiolabelled derivative incorporating 18F is used to study MAO-B inhibition in both in vivo and in vitro experiments.
Diseases of the endocrine glands are common, including conditions such as diabetes mellitus, thyroid disease, and obesity. Endocrine disease is characterized by irregulated hormone release (a productive pituitary adenoma), inappropriate response to signalling (hypothyroidism), lack of a gland (diabetes mellitus type 1, diminished erythropoiesis in chronic kidney failure), or structural enlargement in a critical site such as the thyroid (toxic multinodular goitre). Hypofunction of endocrine glands can occur as a result of the loss of reserve, hyposecretion, agenesis, atrophy, or active destruction. Hyperfunction can occur as a result of hypersecretion, loss of suppression, hyperplastic, or neoplastic change, or hyperstimulation. Endocrinopathies are classified as primary, secondary, or tertiary. Primary endocrine disease inhibits the action of downstream glands. Secondary endocrine disease is indicative of a problem with the pituitary gland. Tertiary endocrine disease is associated with dysfunction of the hypothalamus and its releasing hormones. As the thyroid, and hormones have been implicated in signaling distant tissues to proliferate, for example, the estrogen receptor has been shown to be involved in certain breast cancers. Endocrine, paracrine, and autocrine signaling have all been implicated in proliferation, one of the required steps of oncogenesis. Other common diseases that result from endocrine dysfunction include Addison's disease, Cushing's disease and Grave's disease.
Sources: en.wikipedia.org
In response to this, the junctional epithelium proliferates and grows into the vacant underlying spaces, effectively causing the level of its attachment to migrate towards apically, revealing more tooth structure than is normally evident supragingivally (above the level of the gumline) in health. While many established lesions continue to the advanced lesion (below), most either remain as established lesions for decades or indefinitely; the mechanisms behind this phenomenon are not well understood.
Reduce particle size, for example by tempering chocolate Reduce particle density, by incorporating air pockets Increase the viscosity of the milk, by adding thickening agents Carrageenan is used at very low concentrations to form an imperceptible weak gel that prevents the large, dense particles of chocolate from sedimentation. Ready to drink chocolate milk should be refrigerated like unflavored milk, except some ultra-high temperature (UHT) pasteurized drinks, which can be stored at room temperature. However, it is generally served cold. The nutritional qualities of chocolate milk are the subject of debate: while some studies criticize the high sugar content of chocolate milk, other studies suggest that chocolate milk is nutritionally superior to white.
In the United States, cream soda is often vanilla-flavored and is either clear or colored a light golden brown or pink. Red, orange, and blue colored variants of the plain soda are also made. Popular brands include:
== Major families == The barrier for a regular protein to become a selenoprotein is relatively high due to the requirement for a SECIS element. As a result, new selenoprotein families do not easily appear. It is also not uncommon for these families to include non-selenoprotein descendants, as (mainly terristial) selenium-poor environments provide a fitness advantage to an organism that has lower requirements of selenium. The below will focus on families found in humans.
==== Renal cell carcinoma ==== The VHL (Von Hippel–Lindau) gene encodes a component of an E3 ubiquitin ligase. VHL complex targets a member of the hypoxia-inducible transcription factor family (HIF) for degradation by interacting with the oxygen-dependent destruction domain under normoxic conditions. HIF activates downstream targets such as the vascular endothelial growth factor (VEGF), promoting angiogenesis. Mutations in VHL prevent degradation of HIF and thus lead to the formation of hypervascular lesions and renal tumors.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.